The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Antibiotics in the clinical pipeline in 2013
Open accessAbstract
The continued emergence of multi-drug-resistant bacteria is a major public health concern. The identification and development of new antibiotics, especially those with new modes of action, is imperative to help treat these infections. This review lists the 22 new antibiotics launched since 2000 and details the two first-in-class antibiotics, fidaxomicin (1) and bedaquiline (2), launched in 2011 and 2012, respectively. The development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of the 49 compounds and 6 β-lactamase/β-lactam combinations in active clinical development are discussed, as well as compounds that have been discontinued from clinical development since 2011. New antibacterial pharmacophore templates are also reviewed and analyzed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Lipid A Modification Systems in Gram-Negative Bacteria
Raetz, C. R. H., Reynolds, C. M., Trent, M. S., & Bishop, R. E. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.010307.145803 · Cited by 1,340
Thoughts and facts about antibiotics: Where we are now and where we are heading
Bérdy, J. (2012) · The Journal of Antibiotics · doi:10.1038/ja.2012.27 · Cited by 1,165
Wellington, E. M., Boxall, A. B., Cross, P., Feil, E. J., Gaze, W. H., Hawkey, P. M., Johnson-Rollings, A. S., Jones, D. L., Lee, N. M., Otten, W., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70317-1 · Cited by 1,122
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils
Turner, J., Cho, Y., Dinh, N.-N., Waring, A. J., & Lehrer, R. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2206 · Cited by 798
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus
Reading, C., & Cole, M. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.5.852 · Cited by 739
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., et al. (2008) · Science · doi:10.1126/science.1164571 · Cited by 628
Oren, Z., Lerman, J. C., Gudmundsson, G. H., Agerberth, B., & Shai, Y. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3410501 · Cited by 599
Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein
Larrick, J. W., Hirata, M., Balint, R. F., Lee, J., Zhong, J., & Wright, S. C. (1995) · Infection and Immunity · doi:10.1128/iai.63.4.1291-1297.1995 · Cited by 573
A comprehensive summary of LL-37, the factotum human cathelicidin peptide
Vandamme, D., Landuyt, B., Luyten, W., & Schoofs, L. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.11.009 · Cited by 567
Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa
Srinivas, N., Jetter, P., Ueberbacher, B. J., Werneburg, M., Zerbe, K., Steinmann, J., Van der Meijden, B., Bernardini, F., Lederer, A., Dias, R. L. A., et al. (2010) · Science · doi:10.1126/science.1182749 · Cited by 554
Tew, G. N., Scott, R. W., Klein, M. L., & DeGrado, W. F. (2010) · Accounts of Chemical Research · doi:10.1021/ar900036b · Cited by 552
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Modulating immunity as a therapy for bacterial infections
Hancock, R. E. W., Nijnik, A., & Philpott, D. J. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2745 · Cited by 535
Kokryakov, V. N., Harwig, S. S. L., Panyutich, E. A., Shevchenko, A. A., Aleshina, G. M., Shamova, O. V., Korneva, H. A., & Lehrer, R. I. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80175-t · Cited by 518
Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05708-11 · Cited by 504
Cooper, M. A., & Shlaes, D. (2011) · Nature · doi:10.1038/472032a · Cited by 474
Self-citationMode of Action of the Antimicrobial Peptide Indolicidin
Falla, T. J., Karunaratne, D. N., & Hancock, R. E. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19298 · Cited by 461
Triclosan: a widely used biocide and its link to antibiotics
Schweizer, H. (2001) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(01)00273-7 · Cited by 447
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
Koller, W. C., Lyons, K., Pahwa, R., & Sf, S. W. (2002) · Cited by 421
An anti-infective peptide that selectively modulates the innate immune response
Scott, M. G., Dullaghan, E., Mookherjee, N., Glavas, N., Waldbrook, M., Thompson, A., Wang, A., Lee, K., Doria, S., Hamill, P., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1288 · Cited by 403
Naturally-occurring beta-lactamase inhibitors with antibacterial activity
BROWN, A. G., BUTTERWORTH, D., COLE, M., HANSCOMB, G., HOOD, J. D., READING, C., & ROLINSON, G. N. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.668 · Cited by 399
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Prokocimer, P., De Anda, C., Fang, E., Mehra, P., & Das, A. (2013) · JAMA · doi:10.1001/jama.2013.241 · Cited by 361
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Evolution of antibiotic resistance at non-lethal drug concentrations
Andersson, D. I., & Hughes, D. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.005 · Cited by 339
Natural products — The future scaffolds for novel antibiotics?
Butler, M. S., & Buss, A. D. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.012 · Cited by 337
Self-citationThe mechanism of action of PA-824: Novel insights from transcriptional profiling
Manjunatha, U., Boshoff, H. I. M., & Barry, C. E. (2009) · Communicative & Integrative Biology · doi:10.4161/cib.2.3.7926 · Cited by 319
De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers
Choi, S., Isaacs, A., Clements, D., Liu, D., Kim, H., Scott, R. W., Winkler, J. D., & DeGrado, W. F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811818106 · Cited by 308
Actinonin, a Naturally Occurring Antibacterial Agent, Is a Potent Deformylase Inhibitor
Chen, D. Z., Patel, D. V., Hackbarth, C. J., Wang, W., Dreyer, G. B., Young, D. C., Margolis, P. S., Wu, C., Ni, Z.-J., Trias, J., et al. (2000) · Biochemistry · doi:10.1021/bi992245y · Cited by 298
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Self-citationThe oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Synthesis and Spectrum of the Neoglycoside ACHN-490
Aggen, J. B., Armstrong, E. S., Goldblum, A. A., Dozzo, P., Linsell, M. S., Gliedt, M. J., Hildebrandt, D. J., Feeney, L. A., Kubo, A., Matias, R. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00572-10 · Cited by 243
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, K. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.026 · Cited by 241
Photodynamic Effects of Novel XF Porphyrin Derivatives on Prokaryotic and Eukaryotic Cells
Maisch, T., Bosl, C., Szeimies, R.-M., Lehn, N., & Abels, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1542-1552.2005 · Cited by 232
Page, M. G. P., Dantier, C., & Desarbre, E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-09 · Cited by 227
Antibiotics and antibiotic resistance: A bitter fight against evolution
Rodríguez-Rojas, A., Rodríguez-Beltrán, J., Couce, A., & Blázquez, J. (2013) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2013.02.004 · Cited by 223
Haagsma, A. C., Abdillahi-Ibrahim, R., Wagner, M. J., Krab, K., Vergauwen, K., Guillemont, J., Andries, K., Lill, H., Koul, A., & Bald, D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01393-08 · Cited by 221
Lee, R. E., Protopopova, M., Crooks, E., Slayden, R. A., Terrot, M., & Barry, C. E. (2003) · Journal of Combinatorial Chemistry · doi:10.1021/cc020071p · Cited by 207
Locke, J. B., Hilgers, M., & Shaw, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-09 · Cited by 205
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
Zhanel, G. G., Lawson, C. D., Zelenitsky, S., Findlay, B., Schweizer, F., Adam, H., Walkty, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.25 · Cited by 201
In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor
Bonnefoy, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh358 · Cited by 185
Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity.
COOPER, R. D. G., SNYDER, N. J., ZWEIFEL, M. J., STASZAK, M. A., WILKIE, S. C., NICAS, T. I., MULLEN, D. L., BUTLER, T. F., RODRIGUEZ, M. J., HUFF, B. E., et al. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.575 · Cited by 181
Two decades of imipenem therapy
Rodloff, A. C., Goldstein, E. J. C., & Torres, A. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl354 · Cited by 171
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3118-3124.2002 · Cited by 170
A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption
Isaksson, J., Brandsdal, B. O., Engqvist, M., Flaten, G. E., Svendsen, J. S. M., & Stensen, W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200450h · Cited by 169
Origin, structure, and activity in vitro and in vivo of dalbavancin
Malabarba, A., & Goldstein, B. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki005 · Cited by 167
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
Howarth, T. T., Brown, A. G., & King, T. J. (1976) · J. Chem. Soc., Chem. Commun. · doi:10.1039/c3976000266b · Cited by 162
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
Gin, A. S., Dilay, L., Karlowsky, J. A., Walkty, A. J., Rubinstein, E., & Zhanel, G. G. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.365 · Cited by 153
Are pleuromutilin antibiotics finally fit for human use?
Novak, R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06219.x · Cited by 151
Hirsch, E. B., Ledesma, K. R., Chang, K., Schwartz, M. S., Motyl, M. R., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05927-11 · Cited by 145
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa
Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., & Hatano, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-06 · Cited by 140
Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent
Im, W. B., Choi, S. H., Park, J., Choi, S. H., Finn, J., & Yoon, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.014 · Cited by 139
The pleuromutilin antibiotics: a new class for human use.
Novak, R., & Shlaes, D. M. (2010) · PubMed · Cited by 135
New β‐lactam–β‐lactamase inhibitor combinations in clinical development
Shlaes, D. M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12010 · Cited by 130
PARENTI, F., PAGANI, H., & BERETTA, G. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.247 · Cited by 128
Xiao, X.-Y., Hunt, D. K., Zhou, J., Clark, R. B., Dunwoody, N., Fyfe, C., Grossman, T. H., O’Brien, W. J., Plamondon, L., Rönn, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201465w · Cited by 126
A Concise Synthesis of a β-Lactamase Inhibitor
Mangion, I. K., Ruck, R. T., Rivera, N. R., Huffman, M. A., & Shevlin, M. (2011) · Organic Letters · doi:10.1021/ol202195n · Cited by 125
A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin
Guskey, M. T., & Tsuji, B. T. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.1.80 · Cited by 123
Crowther, G. S., Baines, S. D., Todhunter, S. L., Freeman, J., Chilton, C. H., & Wilcox, M. H. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks359 · Cited by 120
Kaplan, N., Albert, M., Awrey, D. E., Bardouniotis, E., Berman, J., Clarke, T. E., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-12 · Cited by 120
Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection
LaMarche, M. J., Leeds, J. A., Amaral, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201685h · Cited by 116
Antimicrobial mechanism of lantibiotics
Islam, M. R., Nagao, J.-I., Zendo, T., & Sonomoto, K. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120190 · Cited by 116
Recent development of potent analogues of oxazolidinone antibacterial agents
Michalska, K., Karpiuk, I., Król, M., & Tyski, S. S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.036 · Cited by 115
Domain 5 of High Molecular Weight Kininogen Is Antibacterial
Nordahl, E. A., Rydengård, V., Mörgelin, M., & Schmidtchen, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507249200 · Cited by 111
Crandon, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01989-12 · Cited by 108
Preserving the Lifesaving Power of Antimicrobial Agents
Hughes, J. M. (2011) · JAMA · doi:10.1001/jama.2011.279 · Cited by 106
Wallis, R. S., Jakubiec, W., Kumar, V., Silvia, A. M., Paige, D., Dimitrova, D., Li, X., Ladutko, L., Campbell, S. M., Friedland, G. H., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/655471 · Cited by 105
N -Chloramines, a Promising Class of Well-Tolerated Topical Anti-Infectives
Gottardi, W., Debabov, D. V., & Nagl, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02132-12 · Cited by 101
Coronelli, C., White, R. J., Lancini, G., & PARENTI, F. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.253 · Cited by 101
Improving known classes of antibiotics: an optimistic approach for the future
Bush, K. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.003 · Cited by 100
Actinonin: an Antibiotic Substance produced by an Actinomycete
Gordon, J. J., KELLY, B. K., & MILLER, G. A. (1962) · Nature · doi:10.1038/195701b0 · Cited by 99
Theriault, R. J., Karwowski, J. P., JACKSON, M., Girolami, R. L., SUNGA, G. N., VOJTKO, C. M., & COEN, L. J. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.567 · Cited by 99
Farrell, D. J., Robbins, M. J., Rhys‐Williams, W., & Love, W. G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-10 · Cited by 98
Galani, I., Souli, M., Daikos, G. L., Chryssouli, Z., Poulakou, G., Psichogiou, M., Panagea, T., Argyropoulou, A., Stefanou, I., Plakias, G., et al. (2012) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000015 · Cited by 96
Ooi, N., Miller, K., Randall, C. P., Rhys‐Williams, W., Love, W. C., & Chopra, I. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp409 · Cited by 94
XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity
Ooi, N., Miller, K., Hobbs, J. K., Rhys‐Williams, W., Love, W. C., & Chopra, I. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp299 · Cited by 92
Livermore, D. M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt118 · Cited by 90
Antibiotics in development targeting protein synthesis
Sutcliffe, J. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06323.x · Cited by 89
Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination.
Hochlowski, J. E., Swanson, S., RANFRANZ, L. M., Whittern, D. N., BUKO, A. M., & McAlpine, J. B. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.575 · Cited by 88
AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
Karlowsky, J. A., Kaplan, N., Hafkin, B., Hoban, D. J., & Zhanel, G. G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00400-09 · Cited by 88
Gurumurthy, M., Mukherjee, T., Dowd, C. S., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08404.x · Cited by 88
Noel, G. J., Draper, M. P., Hait, H. I., Tanaka, S. K., & Arbeit, R. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00948-12 · Cited by 86
Sequestosome-1/p62 Is the Key Intracellular Target of Innate Defense Regulator Peptide
Yu, H. B., Kielczewska, A., Rozek, A., Takenaka, S., Li, Y., Thorson, L., Hancock, R. E. W., Guarna, M. M., North, J. R., Foster, L. J., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c109.073627 · Cited by 84
Towards new business models for R&D for novel antibiotics
So, A. D., Gupta, N., Brahmachari, S. K., Chopra, I., Munos, B. H., Nathan, C., Outterson, K., Paccaud, J. P., Payne, D. J., Peeling, R. W. W., et al. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.006 · Cited by 83
Rχ-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance
Skripkin, E. A., McConnell, T., DeVito, J., Lawrence, L. E., Ippolito, J. A., Duffy, E. M., Sutcliffe, J. A., & Franceschi, F. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-07 · Cited by 80
Mascio, C. T. M., Mortin, L. I., Howland, K., Praagh, A. D. G. V., Zhang, S., Arya, A., Chuong, C. L., Kang, C., Li, T., & Silverman, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-12 · Cited by 79
Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J. M., & Kwak, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm236 · Cited by 77
Saravolatz, L. D., Pawlak, J., Johnson, L., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00194-12 · Cited by 76
Bertrand, D., Bertrand, S., Neveu, E., & FERNANDES, P. B. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-10 · Cited by 76
Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
Clark, R. B., Hunt, D. K., He, M., Achorn, C., Chen, C.-L., Deng, Y., Fyfe, C., Grossman, T. H., Hogan, P. C., O’Brien, W. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201467r · Cited by 74
Castanheira, M., Sader, H. S., Farrell, D. J., Mendes, R. E., & Jones, R. N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00817-12 · Cited by 74
Lipiarmycin, a new antibiotic from Actinoplanes. III. Mechanism of action.
SERGIO, S., PIRALI, G., White, R. J., & PARENTI, F. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.543 · Cited by 73
Tedizolid (TR-701): a new oxazolidinone with enhanced potency
Kanafani, Z. A., & Corey, G. R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.660250 · Cited by 73
In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens
Lawrence, L. E., Danese, P. N., DeVito, J. A., Franceschi, F. J., & Sutcliffe, J. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01383-07 · Cited by 72
The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site
Tupin, A., Gualtiéri, M., Léonetti, J., & Brodolin, K. L. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.135 · Cited by 71
Stubbings, W., Leow, P., Yong, G. C., Goh, F. Q. Y., Körber-Irrgang, B., Kresken, M., Endermann, R., & Labischinski, H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-10 · Cited by 71
Boucher, H. W. (2010) · Clinical Infectious Diseases · doi:10.1086/647937 · Cited by 69
Are natural products still the best source for antibacterial discovery? The bacterial entry factor
Silver, L. L. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.5.487 · Cited by 67
Isolation and structure determination
Howse, P. E., Stevens, I. D. R., & Jones, O. T. (1998) · Springer eBooks · doi:10.1007/978-94-011-5344-7_6 · Cited by 65
Developing new antibacterials through natural product research
Kirst, H. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.779666 · Cited by 64
Peptides As The Next Generation of Anti-Infectives
Mercer, D. K., & O′Neil, D. A. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.213 · Cited by 63
Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development
Ronn, M., Zhu, Z., Hogan, P. C., Zhang, W., Niu, J., Katz, C. E., Dunwoody, N., Gilicky, O., Deng, Y., Hunt, D. K., et al. (2013) · Organic Process Research & Development · doi:10.1021/op4000219 · Cited by 62
Emergence of antibiotic resistance: need for a new paradigm
Rolain, J., Cantón, R., & Cornaglia, G. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03902.x · Cited by 59
Higgins, P. G., Stubbings, W., Wisplinghoff, H., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01637-09 · Cited by 59
Leeds, J. A., Sachdeva, M., Mullin, S., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06354-11 · Cited by 58
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06305-11 · Cited by 57
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05655-11 · Cited by 56
van Delden, C., Page, M. G. P., & Köhler, T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02474-12 · Cited by 54
Snydman, D. R., Jacobus, N. V., & McDermott, L. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06257-11 · Cited by 52
Lemaire, S., Kosowska-Shick, K., Appelbaum, P. C., Verween, G., Tulkens, P. M., & Françoise Van Bambeke, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01724-09 · Cited by 51
Putnam, S. D., Sader, H. S., Farrell, D. J., Biedenbach, D. J., & Castanheira, M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.08.021 · Cited by 48
Rodgers, W., Frazier, A. D., & Champney, W. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02316-12 · Cited by 48
Farrell, D. J., Robbins, M. J., Rhys‐Williams, W., & Love, W. G. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.02.008 · Cited by 47
de Souza, N. J., Gupte, S. V., Deshpande, P. K., Desai, V. N., BHAWSAR, S. B., Yeole, R. D., Shukla, M. C., Strahilevitz, J., Hooper, D. C., Bozdoğan, B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050035f · Cited by 47
Bouza, E., & Burillo, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.048 · Cited by 46
New horizons for host defense peptides and lantibiotics
Dawson, M. J., & Scott, R. W. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.006 · Cited by 45
Zhou, J., Bhattacharjee, A., Chen, S., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.014 · Cited by 44
Gonzales, F. P., Felgenträger, A., Bäumler, W., & Maisch, T. (2013) · Future Microbiology · doi:10.2217/fmb.13.44 · Cited by 43
Boakes, S., Appleyard, A. N., Cortés, J., & Dawson, M. J. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.48 · Cited by 43
Moir, D. T., Opperman, T. J., Butler, M. M., & Bowlin, T. L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.004 · Cited by 40
Self-citationSpellberg, B. J., Sharma, P., & Rex, J. H. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3560-c1 · Cited by 40
Sader, H. S., Flamm, R. K., & Jones, R. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02436-12 · Cited by 39
Dalhoff, A., Schubert, S., & Ullmann, U. (2005) · Infection · doi:10.1007/s15010-005-8206-y · Cited by 39
Höfer, B., Dantier, C., Gebhardt, K., Desarbre, E., Schmitt‐Hoffmann, A. H., & Page, M. G. P. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks527 · Cited by 39
Farrell, D. J., Castanheira, M., Sader, H. S., & Jones, R. N. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.08.010 · Cited by 37
Antimicrobial activities of LL-37 and its truncated variants against Burkholderia thailandensis
Kanthawong, S., Bolscher, J. G. M., Veerman, E. C. I., van Marle, J., Nazmi, K., Wongratanacheewin, S., & Taweechaisupapong, S. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.031 · Cited by 37
Parsons, J. B., Kukula, M., Jackson, P. D., Pulse, M., Simecka, J. W., Valtierra, D., Weiss, W. J., Kaplan, N., & Rock, C. O. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02307-12 · Cited by 33
Ting, L. S. L., Præstgaard, J., Grunenberg, N. A., Yang, J. C., Leeds, J. A., & Pertel, P. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00867-12 · Cited by 33
Bhagwat, S., McGhee, P., Kosowska-Shick, K., Patel, M. V., & Appelbaum, P. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01150-08 · Cited by 32
Overcoming the challenges to developing new antibiotics
Shlaes, D. M., & Spellberg, B. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.010 · Cited by 30
Tenover, F. C., Tickler, I. A., Armstrong, E. S., Kubo, A., López, S., Persing, D. H., & Miller, G. H. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.05.016 · Cited by 29
Structure and biological activity of lipiarmycin B.
CAVALLERI, B., Arnone, A., Modugno, E. D., Nasini, G., & Goldstein, B. P. (1988) · The Journal of Antibiotics · doi:10.7164/antibiotics.41.308 · Cited by 27
N-Chloro-2,2-dimethyltaurines: a new class of remarkably stable N-chlorotaurines
Wang, L., Khosrovi, B., & Najafi, R. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.02.038 · Cited by 27
Gordon, J. J., Devlin, J. P., East, A. J., Ollis, W. D., Sutherland, I. O., Wright, D. E., & Ninet, L. (1975) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19750000819 · Cited by 27
Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2
Morrow, B. J., Abbanat, D., Baum, E. Z., Crespo‐Carbone, S. M., Davies, T. A., He, W., Shang, W., Queenan, A. M., & Lynch, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00470-11 · Cited by 27
Resolving Biofilm Infections: Current Therapy and Drug Discovery Strategies
Ranall, M. V., Butler, M. S., Blaskovich, M. A. T., & Cooper, M. A. (2012) · Current Drug Targets · doi:10.2174/138945012803530251 · Cited by 26
Self-citationHead-to-Head Prenyl Tranferases: Anti-Infective Drug Targets
Lin, F., Liu, Y.-L., Li, K., Cao, R., Zhu, W., Axelson, J. C., Pang, R., & Oldfield, E. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300208p · Cited by 23
Garrison, M. W., Kawamura, N. M., & Wen, M. M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.112 · Cited by 21
Waites, K. B., Reddy, N. B., Crabb, D. M., & Duffy, L. B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2541-2542.2005 · Cited by 21
Laxminarayan, R., & Powers, J. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3560 · Cited by 20
Stieglitz rearrangement of N,N-dichloro-β,β-disubstituted taurines under mild aqueous conditions
Shiau, T. P., Houchin, A., Nair, S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.109 · Cited by 16
(2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2813 · Cited by 4
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Self-citationSimons, A., Alhanout, K., & Duval, R. E. (2020) · Microorganisms · doi:10.3390/microorganisms8050639 · Cited by 547
Metadata
- Authors
- Butler, M. S., Blaskovich, M. A., & Cooper, M. A.
- Venue
- The Journal of Antibiotics
- Published
- 2013-09-04
- Volume
- 66
- Issue
- 10
- Pages
- 571-591
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W2916084778
- Cited by
- 433
- References
- 156
- FWCI
- 28.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.